Shares of TransEnterix, Inc. (NYSE:TRXC) decreased 4.81% to $2.57 on Thursday. The share price is trading in a range of 2.56 – 2.70 (Price in Dollars).
The stock exchanged hands 3.01M shares versus average trading capacity of 3.25M shares, while its shares’ total market worth is $555.43M. TransEnterix, Inc. (NYSE:TRXC) shares were trading -63.18% below from the 52-week high price mark of $6.98 and +102.36% above from the 52-week price bottom of $1.27. However the company observed 52 week high price on Nov 7, 2017 and witnessed 52 week low price on Nov 13, 2017.
The company employs 119 people, over the last 12 months has generated revenue of $20.00 million and has a net income of $-131.50 Million.
The company’s EPS growth in prior 5 years was 41.60%. In the liquidity ratio analysis; current ratio was 8.80 while debt to equity ratio was 0.12.
TransEnterix, Inc. (NYSE:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, dislcosed the Company received FDA 510(k) clearance for its Senhance™ Ultrasonic System.
“Advanced energy devices are used within a high percentage of cases across a wide range of procedures, which make them a critical tool for laparoscopic surgeons,” said Todd M. Pope, TransEnterix president and CEO. “We believe the addition of the Senhance Ultrasonic System is significant and broadens the attractiveness of the Senhance platform and digital laparoscopy for surgeons in the U.S.”
Advanced energy devices, including ultrasonic devices, represent some of the most versatile and critical tools for surgeons in minimally invasive surgery. These instruments deliver controlled energy to effectively ligate and divide tissue, and minimize thermal injury to surrounding structures. The Company’s Senhance Ultrasonic System is now available in the U.S., as well as all countries that accept a CE Mark.
“The addition of ultrasonic technology is a significant expansion of the Senhance system capability preferred by many surgeons during complex procedures,” said Dr. Steven D. McCarus, MD, FACOG, Chief of Gynecologic Surgery at Florida Hospital Celebration Health. “Combining advanced energy tools with the precision, control, haptics and ergonomics of the Senhance digital interface may allow many surgeons to confidently use this technology across the broadest range of pathology and patients.”
The Senhance System is the first new abdominal robotic surgery platform to receive FDA clearance since 2000, and is the first and only digital laparoscopic surgical platform to offer the security of haptic force feedback that allows surgeons to feel the forces the instruments generate when handling delicate tissue. It is also the first robotic surgical system to offer reusable instruments that help keep per-procedure costs similar to that of traditional laparoscopic surgeries, as well as 3 mm instruments for microlaparoscopic procedures that enable virtually scarless incisions for patients. These advanced technologies exclusive to Senhance were designed to pave the way to the future of robotic surgery by improving the patient and surgeon experience, while helping to lower per-procedure costs and ultimately healthcare costs in general for hospitals and patients.
In the U.S. the Senhance System is cleared for laparoscopic colorectal, gynecological, inguinal hernia and cholecystectomy (gallbladder removal) surgery.
TransEnterix institutional ownership is held at 35.10% while insider ownership was 0.30%. Its EPS was $-0.67 while outstanding shares of the company were 210.74 million. The Company’s Net profit margin was 0.00% while gross profit margin was 29.70%. TRXC last month stock price volatility remained 6.67%.
The stock is now trading at a distance of -5.20% from 20-day simple moving average. The company’s price sits -6.93% below from its 50-day moving average of $2.60 and -32.79% away from the stock’s 200-day moving average which is $4.07.
TransEnterix, Inc. (NYSE:TRXC) currently has a PEG ratio of 0.00 where as its P/E ratio is 0.00. The company’s price to sales ratio for trailing twelve months is 27.08 and price to book ratio for most recent quarter is 3.29, whereas price to cash per share for the most recent quarter is 6.65. TransEnterix, Inc. (NYSE:TRXC)’s price to free cash flow for trailing twelve months is 0.00. Its quick ratio for most recent quarter is 8.00 along with current ratio for most recent quarter of 8.80. Total debt to equity ratio of the company for most recent quarter is 0.12 whereas long term debt to equity ratio for most recent quarter is 0.12. TransEnterix, Inc. (NYSE:TRXC) has a Return on Assets of -54.40%. The company currently has a Return on Equity of -75.60% and Return on Investment of -30.50%.